Characteristics | Results |
---|---|
Number of organ transplant recipients | n = 26 (26 out of 1,106; 2.35%) |
Age (years) | 39.5 (range 19–64) |
Gender (Male) | n = 17 (65.4%) |
Type of organ transplantation | |
Kidney | n = 14 (53.8%) |
Liver | n = 8 (30.8%); due to HBV cirrhosis (n = 1), HCV cirrhosis with/without HCC (n = 3), autoimmune hepatitis (n = 1), Wilson disease (n = 2), cryptogenic cirrhosis (n = 1) |
Bone marrow | n = 4 (15.4%) |
Complications after transplantation | |
Graft rejection | n = 6 (23.1%); kidney (n = 1), liver (n = 4), bone marrow (n = 1) |
Febrile neutropenia | n = 3 (11.5%) |
Clinical/laboratory presentations | |
Hyperbilirubinemia | n = 6 (23.1%) |
Elevation of AST or ALT > 100 U/L | n = 18 (69.2%) |
Liver function test (All 26 cases) | |
AST (U/L) | 125 (25–915) |
ALT (U/L) | 243 (34–1,974) |
ALP (U/L) | 193 (51–677) |
TB (mg/dL) | 3.4 (0.3–35.4) |
Timing of anti-HEV antibody test after organ transplantation | |
< 1 month | n = 4 (15.4%) |
1 month – 1 year | n = 4 (15.4%) |
> 1 year | n = 18 (69.2%): 1–3 years (n = 8; 30.8%), 3–5 years (n = 4; 15.4%), 5–10 years (n = 6; 23.1%) |
Results of anti-HEV antibody test | |
Positive anti-HEV IgG antibody | n = 11 (42.3%) |
Positive anti-HEV IgM antibody | n = 10 (38.5%) |
Liver function test (each group) | Anti-HEV serological statuses | |||
---|---|---|---|---|
IgG-/IgM- (n = 11) | IgG + /IgM- (n = 5) | IgG-/IgM + (n = 4) | IgG + /IgM + (n = 6) | |
AST (U/L) | 51 (28–133) | 102.5 (25–474) | 136 (56–915) | 55 (33–117) |
ALT (U/L) | 119 (34–455) | 156 (81–301) | 251.5 (152–1974) | 108 (53–386) |
ALP (U/L) | 178 (62–677) | 150.5 (102–333) | 179 (67–348) | 95 (51–134) |
TB (mg/dL) | 1.1(0.4–35.4) | 1.5 (0.5–27.6) | 0.8 (0.6–2.3) | 0.5 (0.3–0.7) |